TBC1D3H: A Potential Drug Target and Biomarker for Chronic Pain

Target Name: TBC1D3H

NCBI ID: G729877

TBC1D3H

Other Name(s): TBC1 domain family member 3-like | TBC1 domain family member 3H | TBC3H_HUMAN

TBC1D3H: A Potential Drug Target and Biomarker for Chronic Pain

Introduction

Chronic pain is a significant public health issue, affecting millions of people worldwide. The persistent and severe nature of chronic pain can have a significant impact on an individual's quality of life, leading to disability and reduced productivity. In addition, chronic pain can also have significant economic costs, including healthcare expenses and lost productivity. Therefore, there is a need for effective pain treatments that can provide lasting relief.

The TBC1D3H gene

The TBC1D3H gene is a member of the TBC1 domain family, which is known for its involvement in various cellular processes, including cell signaling, DNA replication, and repair, among others. The TBC1D3H gene has been identified as a potential drug target for chronic pain.

The structure and function of TBC1D3H

TBC1D3H is a gene that encodes a protein known as TBC1D3H. The protein has a molecular weight of approximately 42 kDa and a pre-fusion cleavage structure with a distinct N-terminus and a C-terminus. The N-terminus of TBC1D3H contains a putative transmembrane domain, which is involved in the protein's localization and interactions with other cellular components. The C-terminus of TBC1D3H contains a T-loop and a handle domain, which are involved in the protein's stability and interactions with other proteins.

The role of TBC1D3H in pain

Several studies have demonstrated that TBC1D3H is involved in the regulation of pain signaling. For example, TBC1D3H has been shown to play a role in the development of neuropathic pain in animal models of chronic pain. Additionally, TBC1D3H has been shown to be involved in the Modulation of pain sensitivity in cancer-induced pain in animal models.

Furthermore, TBC1D3H has also been shown to be involved in the regulation of pain perception and tolerance. For example, TBC1D3H has been shown to play a role in the regulation of pain perception in animal models of chronic pain. Additionally, TBC1D3H has been shown to play a role in the regulation of pain tolerance in cancer-induced pain in animal models.

The potential clinical applications of TBC1D3H

The potential clinical applications of TBC1D3H as a drug target or biomarker for chronic pain are significant. If TBC1D3H is successfully targeted or inhibited, it may provide a lasting relief from chronic pain, leading to improved quality of life and reduced disability. In addition, TBC1D3H may also be used as a biomarker to monitor the effectiveness of pain treatments.

TBC1D3H has also been shown to be involved in the regulation of various cellular processes, including cell signaling, DNA replication, and repair. Therefore, it is possible that TBC1D3H may have unintended effects on other cellular processes, which could be potential drug targets or biomarkers for other diseases.

Conclusion

TBC1D3H is a gene that encodes a protein with potential clinical applications as a drug target or biomarker for chronic pain. The regulation of pain signaling by TBC1D3H is complex and involves multiple cellular processes. Further research is needed to fully understand the role of TBC1D3H in pain and to develop effective pain treatments that can provide lasting relief.

Protein Name: TBC1 Domain Family Member 3H

Functions: Acts as a GTPase activating protein for RAB5. Does not act on RAB4 or RAB11 (By similarity)

The "TBC1D3H Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TBC1D3H comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets